Why the study?
In cardio-oncology, complex pharmacological profiles and narrow therapeutic indices create drug interaction risks that can reduce the efficacy or safety of cardiovascular and cancer therapies.
This AHA scientific statement highlights the critical need for clinicians to recognize and mitigate potential drug-drug interactions between cardiovascular and cancer therapies.
Answers are grounded in this paper and cite their sources.
Clinicians should monitor drug interactions in cardio-oncology; leaves open systematic evaluation of their net clinical impact.
In the cardio-oncology population, drug interactions are of particular importance given the complex pharmacological profile, narrow therapeutic index, and inherent risk of therapies used to manage cardiovascular disease and cancer. Drug interactions may be beneficial or detrimental to the desired therapeutic effect. Clinicians in both cardiology and oncology should be cognizant of these potential drug-drug interactions that may reduce the efficacy or safety of either cardiovascular or cancer therapies. These risks can be mitigated through increased recognition of potential drug-drug interaction, use of alternative medications when possible, and careful monitoring. This scientific statement provides clinicians with an overview of pharmacodynamic and pharmacokinetic drug-drug interactions in patients with cancer exposed to common cardiovascular and cancer medications.
No takes yet. Share an insight, caveat, or question.
Beavers et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: